-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on CytomX Therapeutics, Lowers Price Target to $2.5

Benzinga·04/14/2025 14:49:45
Listen to the news
Piper Sandler analyst Joseph Catanzaro maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and lowers the price target from $3.25 to $2.5.